

ATTORNEY'S CHECK NO.: H0535/7009 (ERG/MAT)

Date of Mailing: January 9, 2002

RCE/1651

# REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995. See The American Inventors Protection Act of 1999 (AIPA).

Application Number	09/359,920
Filing Date	July 22, 1999
First Named Inventor	Howard Green
Group Art Unit	1651
Examiner Name	D. Naff

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.  
**NOTE:** 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, **you** may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) instead of an RCE to be eligible for the patent term adjustment provisions of the AIPA.

## 1. Submission required under 37 C.F.R. § 1.114

### a. Previously submitted

- i. ☐ Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on (Any unentered amendment(s) referred to above will be entered).
- ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on
- iii. ☐ Other

### b. Enclosed is/are:

- i. ☐ Amendment/Reply
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☒ Information Disclosure Statement (IDS) 1449 and cited references
- iv. ☐ Other

## 2. Miscellaneous

- a. ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of \_\_\_ months. (Period of suspension shall not exceed 3 months) and the Fee of \$130.00 under 37 C.F.R. § 1.17(i) is enclosed.
- b. ☐ Other
- 3. ☒ Applicant claims small entity status, See 37 CFR 1.22.
- 4. Fees - The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.
  - a. ☐ Enclosed is a check in the amount of \$370.00 which covers:
    - i. ☒ RCE fee required under 37 C.F.R. § 1.17(e)
    - ii. ☐ Extension of time fee (37 C.F.R. §§ 1.136 and 1.17)
    - iii. ☐ Other
  - b. ☐ Please charge Deposit Account No. 23/2825 in the amount of \$ \_\_\_\_\_ which covers:
    - ☐ RCE fee required under 37 C.F.R. § 1.17(e)
    - ☐ Extension of time fee (37 C.F.R. §§ 1.136 and 1.17)
    - ☐ Other

RECEIVED  
 FEB 04 2002  
 TECH CENTER 1600/2900

01 FC:279  
 01/31/2002 11:11:55  
 00100000 09359920  
 370.00 DP

Serial No. 09/359,920

Art Unit: 1651

5. If the filing of this RCE necessitates an extension of time under 37 CFR §1.136(a), the applicant hereby requests such extension of time.
6. If there is no check enclosed, or if the amount of the enclosed check in this RCE is incorrect, the Director is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 23/2825.

7. CORRESPONDENCE ADDRESS

Correspondence address below

CUSTOMER NUMBER:



23628

OR

RECEIVED  
FEB 04 2002  
TECH CENTER 1600/2900

AGENT'S NAME	Maria A. Trevisan, Reg. No. 48,207				
FIRM NAME	Wolf, Greenfield & Sacks, P.C.				
ADDRESS	600 Atlantic Avenue				
CITY	Boston	STATE	MA	ZIP	02210
COUNTRY	USA	TELEPHONE	(617) 720-3500	FAX	(617) 720-2441

8. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

NAME	Maria A. Trevisan, Reg. No. 48,207
SIGNATURE	
DATE	January 9, 2002

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Box RCE, Commissioner for Patents, Washington, D.C. 20231, on January 9, 2002.

Maria A. Trevisan



Applicant: Howard Green et al.  
Serial No: 09/359,920  
Filed: July 22, 1999  
For: TRANSGLUTAMINASE LINKAGE OF AGENTS TO TISSUE  
Examiner: D. Naff  
Group Art Unit: 1651

ATTORNEY'S DOCKET NO: H0535/7009 (ERG/MAT)  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
FEB 04 2002  
TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on January 9, 2002.

Maria A. Trevisan, Reg. No. 48,207

Commissioner for Patents  
Washington, D.C. 20231

#19  
P.93  
2/20/02

STATEMENT FILED PURSUANT TO THE DUTY OF  
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure has been filed under 37 C.F.R. §1.97(b)(4) before the mailing of a first Office action after the filing of a request for continued examination under §1.114.

No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

The following are remarks concerning the other information cited:

PART IV: Remarks

Documents cited on the attached form PTO-1449 (modified) are enclosed unless otherwise indicated on the attached form PTO-1449 (modified). It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;

2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;

3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

WOLF, GREENFIELD & SACKS, P.C.

By 

Maria A. Trevisan Reg. No. 48,207  
WOLF, GREENFIELD & SACKS, P.C.  
600 Atlantic Avenue  
Boston, MA 02210-2211  
Attorneys for Applicant(s)  
Telephone No. (617) 720-3500

ATTORNEY'S DOCKET NO.: H0535/7009 (ERG/MAT)  
DATE: January 9, 2002  
X01/09/02